PASG vs PMCB

Passage Bio, Inc. vs PharmaCyte Biotech, Inc. — Valuation Comparison 2026

PASG

Biological Products, (No Diagnostic Substances)
Passage Bio, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$5.77
Last close
Models
7/13
Active
VS

PMCB

Biological Products, (No Diagnostic Substances)
PharmaCyte Biotech, Inc.
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$0.83
Last close
Models
3/13
Active

Model-by-Model Comparison

ModelType PASG Fair ValuePASG Upside PMCB Fair ValuePMCB Upside
Bayesian DCF Intrinsic $3.63 -37.1%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $30.86 +434.9% $2.46 +194.8%
PWERM Option-Based $8.02 +38.9% $2.23 +167.6%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PASG vs PMCB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PASG vs PMCB — Which Stock Is More Undervalued?

PMCB scores higher with a 5.1/10 quality rating vs PASG's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Passage Bio, Inc. (PASG) and PharmaCyte Biotech, Inc. (PMCB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PASG currently trades at $5.77 with a QOC of 3.9/10, while PMCB trades at $0.83 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).